Glaukos Corporation (NYSE:GKOS – Get Free Report) Director Gilbert Kliman sold 2,500 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $190.00, for a total value of $475,000.00. Following the transaction, the director directly owned 37,406 shares in the company, valued at $7,107,140. This represents a 6.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Glaukos Price Performance
Glaukos stock traded down $4.30 during mid-day trading on Thursday, hitting $185.25. 791,869 shares of the company were exchanged, compared to its average volume of 942,762. The business’s 50 day simple moving average is $156.20 and its two-hundred day simple moving average is $131.24. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $191.62. The company has a market capitalization of $10.93 billion, a P/E ratio of -57.00 and a beta of 0.78. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46.
Glaukos (NYSE:GKOS – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to analysts’ expectations of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The firm’s revenue for the quarter was up 49.6% compared to the same quarter last year. During the same period last year, the company earned ($0.24) EPS. Analysts forecast that Glaukos Corporation will post -0.35 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Glaukos
Wall Street Analysts Forecast Growth
Several research firms have commented on GKOS. Needham & Company LLC lifted their target price on shares of Glaukos from $150.00 to $201.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research note on Friday, July 17th. Stifel Nicolaus raised their target price on shares of Glaukos from $175.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. JPMorgan Chase & Co. raised their price target on shares of Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Finally, Wells Fargo & Company boosted their price objective on shares of Glaukos from $138.00 to $178.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Glaukos has a consensus rating of “Moderate Buy” and a consensus price target of $178.08.
View Our Latest Stock Analysis on GKOS
Key Glaukos News
Here are the key news stories impacting Glaukos this week:
- Positive Sentiment: Higher analyst price target: BTIG Research raised its target for Glaukos from $193 to $202 and reiterated a “Buy” rating, citing additional potential upside for the shares. Benzinga
- Positive Sentiment: Strong product momentum: Glaukos’ iDose TR glaucoma implant and Epioxa corneal treatment launch are driving record growth, supporting higher 2026 guidance and expanding the company’s ophthalmology platform. The catalysts have helped the stock gain roughly 67% year to date. GKOS Stock Surges 67% Year to Date: What’s Driving the Rally?
- Positive Sentiment: Improving earnings outlook: Zacks Research raised its FY2027 EPS forecast to $0.45 from $0.38 and its FY2028 estimate to $1.70 from $1.56. It also increased several quarterly estimates, signaling expectations for accelerating profitability as newer products gain adoption.
- Neutral Sentiment: Investor-relations event: Management will participate in the Wells Fargo Healthcare Conference on September 9, which could provide updates on iDose TR, Epioxa, guidance and the development pipeline. Glaukos Announces Participation in Wells Fargo Healthcare Conference
- Negative Sentiment: Near-term profitability remains limited: Glaukos is still expected to post a loss for the current fiscal year, and Zacks modestly reduced its Q2 2027 EPS estimate to $0.06 from $0.07. After the sharp rally, these factors may encourage investors to lock in gains and question the stock’s valuation.
About Glaukos
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Featured Articles
- Five stocks we like better than Glaukos
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
